Novartis Pharma AG, 4056, Basel, Switzerland.
Novartis Ireland Limited, 203 Merrion Rd, Dublin, D04 NN12, Ireland.
BMC Cardiovasc Disord. 2022 May 21;22(1):234. doi: 10.1186/s12872-022-02665-y.
Heart failure (HF) is a global illness and is a leading cause of hospitalizations. Recurrent HF hospitalization (HFH) is associated with increased risk of cardiovascular (CV) and all-cause mortality, thereby burdening the health system. Type 2 diabetes mellitus (T2DM) and atrial fibrillation (AF) are two important comorbidities in patients living with HF. This study aims to assess the association between recurrent HFHs with CV and all-cause mortality in patients living with HF and having AF and/or T2DM.
This study was conducted using primary care data from the Clinical Practice Research Datalink database with linkage to hospital data and mortality data. Adults living with HF and with at least 1 HFH were identified from January 2010 to December 2014. Patients were grouped based on the number of recurrent HFHs. During follow-up, all-cause mortality or CV mortality for the HF population with AF and T2DM was recorded.
Overall, 32.9% of 2344 T2DM patients and 28.2% of 4585 AF patients had at least 1 recurrent HFH. The patients were relatively elderly and were predominantly male. The mean number of all-cause hospitalizations in HF patients having T2DM and AF, with ≥ 1 recurrent HFH were significantly higher than patients without recurrent HFH. The annualized mortality rates in CV mortality as the primary cause and for all-cause mortality and increased with recurrent HFHs, in T2DM and AF patients. The risk of CV mortality as primary cause and all cause morality were 5.39 and 3.19 times higher in T2DM patients with 3 recurrent HFHs versus no recurrent HFH. Similarly, the risk of CV mortality as primary cause and all cause morality was 5.98 and 4.3 times higher in AF patients with 3 recurrent HFHs versus those with no recurrent HFH.
Recurrent HFHs are strongly associated with CV mortality and all-cause mortality in HF patients with TD2M or AF. The hospitalization rate highlights the need for treatment and disease management, which will improve the course of the disease and help patients stay out of hospital.
心力衰竭(HF)是一种全球性疾病,也是住院的主要原因。复发性心力衰竭住院(HFH)与心血管(CV)和全因死亡率的风险增加相关,从而给医疗系统带来负担。2 型糖尿病(T2DM)和心房颤动(AF)是 HF 患者的两个重要合并症。本研究旨在评估 HF 合并 AF 和/或 T2DM 患者复发性 HFH 与 CV 和全因死亡率的相关性。
本研究使用来自临床实践研究数据链接数据库的初级保健数据进行,该数据库与医院数据和死亡率数据相链接。从 2010 年 1 月至 2014 年 12 月,确定至少有 1 次 HFH 的 HF 患者。根据复发性 HFH 的数量对患者进行分组。在随访期间,记录 HF 合并 AF 和 T2DM 患者的全因死亡率或 CV 死亡率。
总体而言,2344 例 T2DM 患者中有 32.9%和 4585 例 AF 患者中有 28.2%至少有 1 次复发性 HFH。患者年龄较大,主要为男性。HF 患者中 T2DM 和 AF 合并至少 1 次复发性 HFH 的全因住院次数的平均值明显高于无复发性 HFH 的患者。CV 死亡率作为主要原因以及全因死亡率的年化死亡率随着复发性 HFH 的增加而增加,在 T2DM 和 AF 患者中也是如此。3 次复发性 HFH 的 T2DM 患者的 CV 死亡率作为主要原因和全因死亡率的风险分别是无复发性 HFH 的 5.39 倍和 3.19 倍。同样,3 次复发性 HFH 的 AF 患者的 CV 死亡率作为主要原因和全因死亡率的风险分别是无复发性 HFH 的 5.98 倍和 4.3 倍。
复发性 HFH 与 HF 合并 T2DM 或 AF 患者的 CV 死亡率和全因死亡率密切相关。住院率突出了治疗和疾病管理的必要性,这将改善疾病进程并帮助患者避免住院。